Electropharmacological actions of Ginkgo biloba extract on vascular smooth and heart muscles

Clinica Chimica Acta

Volumn 342, Issue 1-2, 2004, Pages 13-22

  Satoh, Hiroyasu ^a   Nishida, Seiichiro ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Action potentials; Flavonoids; Ginkgo biloba extract; Ionic currents; Terpenoids; Vasodilation

Indexed keywords

BILOBALIDE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; FLAVONOID; GINKGO BILOBA EXTRACT; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; QUERCETIN; RUTOSIDE; TERPENOID;

ACTION POTENTIAL; AORTA MEDIA; CALCIUM CURRENT; CALCIUM TRANSPORT; CHRONOTROPISM; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; ENDOTHELIUM; GINKGO BILOBA; GUINEA PIG; HEART MUSCLE; HEART MUSCLE CELL; HUMAN; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; REVIEW; SINUS NODE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ACTION POTENTIALS; ANIMALS; FLAVONOIDS; GINKGO BILOBA; HEART; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; PATCH-CLAMP TECHNIQUES; PLANT EXTRACTS; TERPENES;

CAVIA PORCELLUS; GINKGO BILOBA; SUS SCROFA;

EID: 1542710205     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.12.014     Document Type: Review

References (58)

1. Dennis J.M., Kenneth J., Kerry H. Efficacy, safety, and use of Ginkgo biloba in clinical and preclinical applications. Altern. Ther. 7:2001;70-90.
2. Huh H., Staba E.J. The botany and chemistry of Ginkgo biloba L. J. Herbs Spices Med. Plants. 1:1992;92-124.
3. Sticher O. Quality of Ginkgo preparations. Planta Med. 59:1993;2-11.
4. Kressmann S., Muller W.E., Blume H.H. Pharmaceutical quality of different Ginkgo biloba brands. J. Pharm. Pharmacol. 54:2002;661-669.
5. Kleijnen J., Knipschild P. Ginkgo biloba for cerebral insufficiency. Br. J. Clin. Pharmacol. 34:1992;352-358.
6. Zhang W.R., Hayashi T., Kitagawa H., Sasaki C., Sakai K., Warita H.et al. Protective effect of Ginkgo biloba extract on rat brain with transient middle cerebral artery occlusion. Neurol. Res. 22:2000;517-521.
7. Vesper J., Hänsegen K.D. Efficacy of Ginkgo biloba in 90 outpatients with cerebral insufficiency caused by old age; results of a placebo-controlled double-blind trial. Phytomedicine. 1:1994;9-16.
8. Kennedy D.O., Scholey A.B., Wesnes K.A. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology. 151:2000;416-423.
9. Le Bars P.L., Katz M.M., Berman N., Itil T.M., Freedman A.M., Schatzberg A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 278:1997;1327-1332.
10. Peters H., Kieser M., Hölscher U. Demonstration of the efficacy of Ginkgo biloba special extract EGb 761® on intermittent claudication - a placebo-controlled, double-blind multicenter trial. VASA. 27:1998;106-110.
11. Diamond B.J., Shiflett S.C., Schoenberger N.E. Ginkgo biloba extract: mechanisms and clinicals indications. Arch. Phys. Med. Rehabil. 81:2000;668-678.
12. Bauer U. 6-Month double-blind randomized clinical trial of Ginkgo biloba extract versus placebo in two parallel groups in patients suffering from peripheral arterial insufficiency. Arzneim. Forsch./Drug Res. 34:1984;716-720.
13. Hamann K.F. Pyhsikalische Therapie des vestibul ären Schwindels in Verbindung mit GBE. Therapiewoche. 35:1985;4586-4590.
14. Weitbrecht W.V., Jansen W. Primär degerative demenz: therapie mit GBE. Plazebokontrollierte doppelblind- und vergleichsstudie. Fortschr. Med. 104:1986;199-202.
15. Haguenauer J.P., Cantenot F., Koskas H., Pierart H. Traitement des traoubles de l'équilibre par l'extrait de Ginkgo biloba. Étude multicentrique à double insu face au placebo. Presse Med. 15:1986;1569-1572.
16. Meyer B. Étude multicentrique randomisée à double insu face au placebo du traitement des acouphénes par l'extrait de Ginkgo biloba. Presse Med. 15:1986;1562-1564.
17. Le Bars P.L., Kieser M., Itil K.Z. A 26-week analysis of a double-blind, placebo-controlled trial of the Ginkgo biloba extract EGb 761 in dementia. Dement. Geriatr. Cogn. Disord. 11:2000;230-237.
18. Chung H.S., Harris A., Kristinsson J.K., Ciulla T.A., Kagemann C., Ritch R. Ginkgo biloba extract increases ocular blood flow velocity. J. Ocul. Pharmacol. Ther. 15:1999;233-240.
19. Klein J., Chatterjee S.S., Loffelholz K. Phospholipid breakdown and choline release under hypoxic conditions: inhibition by bilobalide, a constituent of Ginkgo biloba. Brain Res. 755:1997;347-350.
20. Krieglstein J., Beck T., Seibert A. Influence of an extract of Ginkgo biloba on cerebral blood flow and metabolism. Life Sci. 39:1986;2327-2334.
21. Oberpichler H., Beck T., Abdel-Rahman M.M., Bielenberg G.W., Krieglstein J. Effects of Ginkgo biloba constituents related to protection against brain damage caused by hypoxia. Pharmacol. Res. Commun. 20:1988;349-368.
22. Akiba S., Kawauchi T., Oka T., Hashizume T., Sato T. Inhibitory effect of the leaf extract of Ginkgo biloba L. on oxidative stress-induced platelet aggregation. Biochem. Mol. Biol. Int. 46:1998;1243-1248.
23. Akisu M., Kultursay N., Coker I., Huseyinov A. Platelet-activating factor is an important mediator in hypoxic ischemic brain injury in the newborn rat. Flunarizine and Ginkgo biloba extract reduce PAF concentration in the brain. Biol. Neonate. 74:1998;439-444.
24. Maclennan K.M., Darlington C.L., Smith P.F. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog. Neurobiol. 67:2002;235-257.
25. Janssens D., Michiels C., Delaive E., Eliaers F., Drieu K., Remacle J. Protection of hypoxia-induced ATP decrease in endothelial cells by Ginkgo biloba extract and bilobalide. Biochem. Pharmacol. 50:1995;991-999.
26. Auguet M., Clostre F. Effects of an extract of Ginkgo biloba and diverse substances on the phasic and tonic components of the contraction of an isolated rabbit aorta. Gen. Pharmacol. 14:1983;277-280.
27. Delaflotte S., Augguest M., DeFeudis F.V., Baranes J., Clostre F., Drieu K.et al. Endothelium-dependent relaxation of rabbit isolated aorta produced by carbachol and by Ginkgo biloba extract. Biomed. Biochim. Acta. 43:1984;212-216. [suppl.].
28. Chen X., Salwinski S., Lee T.J.-F. Extracts of Ginkgo biloba and ginsenosides exert cerebral vasorelaxation via a nitric oxide pathway. Clin. Exp. Pharmacol. Physiol. 24:1997;958-959.
29. Kubota Y., Tanaka T., Umegaki K. Ginkgo biloba extract-induced relaxation of rat aorta is associated with increase in endothelial intracellular calcium level. Life Sci. 69:2001;2327-2336.
30. Ca channel-opening activity of Ginkgo biloba extracts and ginsensides in cultured endothelial cells. Clin. Exp. Pharmacol. Physiol. 28:2001;441-445.
31. Waldron G.J., Dong H., Cole W.C., Triggler C.R. Endothelium-dependent hyperporalization of vascular smooth muscle; role for a non-nitric oxide synthase product. Acta Pharmacol. Sin. 17:1996;3-7.
32. + channels and endothelial factors. Br. J. Pharmacol. 123:1998;1533-1540.
33. Quignard J.F., Feleton M., Thollon C., Vilaine J.P., Duhault J., Vanhoutte P.M. Pottasium ions and endothelium-derived hyperpolarizing factor in guinea-pig carotid and porcine coronary arteries. Br. J. Pharmacol. 127:1999;27-37.
34. Chatterjee S.S. Effects of Ginkgo biloba extract on cerebral metabolic processes. Agnoli A., Rapin J.R., Scapagnini V., Weitbrecht W.V. Effects of Ginkgo biloba on organic cerebral impairment. 1985;5-14 John Libbey, London.
35. Chatterjee S.S., Gabard B. Studies on mechanism mechanism of action of an extract of Ginkgo biloba, a drug used for treatment of ischemic vascular diseases. Naunyn-Schmiedeberg's Arch. Pharmacol. 321:1982;207.
36. Liebgott T., Miollan M., Berchadsky Y., Drieu K., Culcasi M., Pietri S. Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res. Cardiol. 95:2000;368-377.
37. Tamargo J., Delgado C., Diez J., Delpon E. Cardiac electrophysiology of PAF-acether antagonists. Braquet P. Ginkgolides. vol. 1:1988;417-431 J.R. Prous, Barcelona.
38. Biber A., Koch E. Bioavailability of ginkgolides and bilobalide from extracts of Ginkgo biloba using GC/MS. Planta Med. 65:1999;192-193.
39. Foutillan J.B., Brisson A.M., Girault J., Ingrand I., Decourt J.P., Drieu K.et al. Phamacokinetic properties of bilobalide and ginkgolides A and B in healthy subjects after intravenous and oral administration of Ginkgo biloba extract (EGb 761). Therapie. 50:1995;137-144.
40. Mauri P., Simonetti P., Gardana C., Minoggio M., Morazoni P., Bombardelli E.et al. Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun. Mass Spectrom. 15:2001;929-934.
41. Erlund I., Kosonen T., Alfthan G., Maenpaa J., Perttunen K., Kenraali J.et al. Pharamacokinetics of quercetin from quercetin and rutin in healthy volunteers. Eur. J. Clin. Pharmacol. 56:2000;545-553.
42. Morand C., Manach C., Crespy V., Remesy C. Respective bioavailability of quercetin aglycone and its glycosides in a rat model. BioFactors. 12:2000;169-174.
43. Oliveira E.J., Watson D.G., Grant M.H. Metabolism of quercetin and kaempferol by rat hepatocytes and the identification of flavonoid glycosides in human plasma. Xenobiotica. 32:2002;279-287.
44. Shinozuka K., Umegaki K., Kubota Y., Tanaka N., Mizuno H., Yamauchi J.et al. Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci. 70:2002;2783-2792.
45. Umegaki K., Saito K., Kubota Y., Sanada H., Yamada K., Shinozuka K. Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats. Jpn. J. Pharmacol. 90:2002;345-351.
46. Nishida S., Satoh H. Mechanisms for vasodilations induced by Ginkgo biloba extract and its main constituent, bilobalide, in rat aorta. Life Sci. 72:2003;2659-2667.
47. Satoh H. Effects of Ginkgo biloba extract and bilobalide, a main constituent, on the ionic currents in guinea pig ventricular cardiomyocytes. Arzneim. Forsch./Drug Res. 53:2003;407-413.
48. + channels and endothelial factors. Br. J. Pharmacol. 123:1998;1533-1540.
49. Nishida S., Satoh H. Comparative vasodilating actions induced by the constituents of Ginkgo biloba extracts. J. Pharm. Sci. 91(Suppl. 1):2003;P134.
50. Catalin M.F., Eugen B., Gabi H., Sebastian S., Ovidu B., Dimitrie D.B. Multiple effects of tyrosine kinase inhibitors on vascular smooth muscle contraction. Eur. J. Pharmacol. 281:1995;29-35.
51. Satoh H. Electropharmacology of Ginkgo biloba extract and the constituents in guinea pig ventricular cardiomyocytes. Jpn. J. Pharmacol. 88(Suppl. 1):2002;259.
52. Satoh H. Cardiac electrophysiological modulation by NS-7, a novel neuroprotective drug, of guinea pig ventricular muscles. Life Sci. 72:2003;1039-1048.
53. Muir A.H., Robb R., McLaren M., Daly F., Belch J.J. The use of Ginkgo biloba in Raynaud's disease: a double-blind placebo-controlled trial. Vasc. Med. 7:2002;265-267.
54. Mouren X., Caillard P., Schwartz F. Study of the anti-ischemic action of EGb 761 in the treatment of peripheral arterial occlusive disease by TcPo2 determination. Angiology. 45:1994;413-417.
55. Thomson G.J.L., Vohra R.K., Carr M.H., Walker M.G. A clinical trial of Ginkgo biloba extract in patients with intermittent claudication. Int. Angiol. 9:1990;75-78.
56. Satoh H., Sperelakis N. Calcium and potassium currents in cultured rat aortic vascular smooth muscle cell lines. Sperelakis N. Ion channels of vascular smooth muscle cells and endothelial cells. 1991;55-63 Academic Press, New York.
57. 2+ current by isoprenaline, carbachol and phorbol ester in cultured rat aortic vascular smooth muscle (A7r5) cells. Gen. Pharmacol. 26:1995;369-379.
58. + current by isoprenaline, carbachol, and phorbol ester in cultured (and fresh) rat aortic vascular smooth muscle cells. Gen. Pharmacol. 27:1996;319-324.